LIPJ inhibitors belong to a distinctive chemical class known for their specific interactions with the LIPJ enzyme. This class of inhibitors is characterized by a unique structural framework that enables them to selectively target and modulate the activity of LIPJ. LIPJ, short for Lipase J, is an enzyme that plays a crucial role in lipid metabolism within biological systems. As a lipase, LIPJ is involved in catalyzing the hydrolysis of ester bonds in lipids, facilitating the breakdown of triglycerides into fatty acids and glycerol. This enzymatic activity is vital for cellular processes related to energy storage and utilization.
The chemical structure of LIPJ inhibitors is meticulously designed to interact with specific binding sites on the LIPJ enzyme, disrupting its normal catalytic function. Researchers have focused on elucidating the intricate molecular mechanisms through which these inhibitors bind to LIPJ, aiming to understand their inhibitory effects at a detailed level. By deciphering the structural nuances of the LIPJ inhibitor interaction, scientists can gain insights into potential applications and implications for lipid metabolism regulation. The study of LIPJ inhibitors contributes to the broader understanding of enzymatic processes involved in lipid metabolism, paving the way for advancements in various fields such as biochemistry and molecular biology.
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, leading to the accumulation of proteins within the cell and potentially inducing a downregulation of protein synthesis, affecting the levels of proteins such as LIPJ if it is involved in ubiquitin-proteasome pathways. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $265.00 $1050.00 | ||
Omipalisib is a potent and selective small-molecule inhibitor of the PI3K and mTOR kinases. By inhibiting these kinases, Omipalisib can suppress the PI3K/AKT/mTOR signaling pathway, leading to decreased protein synthesis and potentially affecting the production of proteins like LIPJ if it is downstream of this pathway. | ||||||